Dr. Vijay Gupta received his Master’s degree in Microbiology from CCS University, Meerut, India and Ph.D. at the Centre for Cellular and Molecular Biology (CCMB), Hyderabad, INDIA (2006). Dr. Gupta was awarded ASCB pre-doctoral travel award to attend ASCB annual meeting in 2005, Carl Storm International Diversity Fellowship to attend the Gordon Research Conference in University of New England, Maine, USA 2006 and later on Royal Society International Incoming Fellowship (2006) from the Royal Society, London, UK to perform research at The University of Bristol where he worked for fifteen months with the honorary title of Royal Society International Research fellow. He joined The Scripps Research Institute, La Jolla, USA on Target Characterization Fellowship funded by Cystic Fibrosis Foundation, USA as CF fellow for five years and then moved to University of California, San Diego as Assistant Project Scientist where he worked till June, 2017.
Dr. Gupta has multidisciplinary research experience in the fields of protein trafficking, cancer and human genetic diseases and has published more than fifteen publications including top-tier journals such as Nature Chemical biology, Developmental Cell, PNAS, JCS and Traffic. He is an invited member of Sigma Xi- Scientific Honor Society, elected 2013, invited member of Cell Stress Society International (CSSI), USA, peer review board member of JoVe and Dove press and has reviewed more than thirty manuscripts. One of the hobbies of Dr. Gupta is popular science writing for the general public, aimed at raising scientific awareness.
Common neurodegenerative diseases such as Parkinson’s Disease, Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA) are characterized by progressive deposition of α-synuclein (α-syn) protein within inclusions referred to as Lewy bodies and glial cytoplasmic inclusions respectively. Amongst the various approaches attempting to tackle the pathological features of synucleinopathies, immunotherapy holds much promise. α-Syn antibodies could potentially block processes leading to the pathogenesis of such neurodegenerative diseases. The limitation of such antibodies is their inefficiency in crossing the Blood-Brain Barrier (BBB). Dr. Gupta’s research interests lies in designing a variety of strategies to develop efficient antibodies or similar molecules with superior BBB cross over capacities.
Farquhar and Pradipta Ghosh. “GIV/Girdin activates Gαi and inhibits Gαs via the same motif”. PNAS. 2016 Sep 27;113(39):E5721-30.
2016Farquhar and Pradipta Ghosh, “CDK5 Activates Guanine Nucleotide Exchange Factor GIV/Girdin to Orchestrate Migration-Proliferation Dichotomy”. PNAS, 2015 Sep 1;112:E4874-83.
2015Farquhar,* and Pradipta Ghosh * “Activation of Gi at the Golgi by GIV/Girdin Imposes Finiteness in Arf1 Signaling”. Dev. Cell 33, 1–15, April 20, 2015.
2015J Proteome Res. 2014 13 (11), PP 4668-4675.
20142013 Jan; 9(1):12-4.
2013“Kinesin-1 (uKHC/KIF5B) is required for bidirectional motility of ER exit sites and efficient ER-to-Golgi transport” Traffic, Volume 9, Issue 11 , Pages 1850-66, (2008).
2008Pubmed link